Description
This assay uses the Meso Scale Discovery® (MSD®) platform.
Consider this assay for the precise measurement of pTau217, a key biomarker associated with Tau pathology in neurodegenerative diseases. The Human MSD® Discovery Assay® pTau217 (MSDPTAU217) is expertly designed to detect pTau217 levels with high sensitivity.
Monitoring pTau217, therefore, offers significant potential for early detection, prognosis, and therapeutic development in neurodegenerative diseases characterized by Tau pathology. Specifically, this biomarker is emerging as a valuable tool for Alzheimer’s disease (AD) diagnosis and tracking disease progression. Moreover, elevated levels of pTau217 have also been linked to other tauopathies, such as frontotemporal dementia and progressive supranuclear palsy, although with varying degrees of specificity.
In summary, the Human MSD® Discovery Assay® pTau217 (MSDPTAU217) leverages the advanced Meso Scale Discovery (MSD) platform to deliver accurate and reliable results. Consequently, this assay is essential for researchers and clinicians seeking to advance understanding and treatment of Tau-related disorders, ultimately providing critical insights into disease mechanisms and therapeutic efficacy.
Ultrasensitive assay that measures phosphorylated Tau at threonine 217 (pTau217) in a single-analyte format.
This assay is optimized for analysis of Serum, Plasma, and CSF samples. If you have another sample type, please contact us prior to ordering this assay.
Click here for information on shipping biological samples for Discovery Assays
Published Research Featuring MSD® pTau217:
- Kivisäkk P, Fatima HA, Cahoon DS, et al. Clinical evaluation of a novel plasma pTau217 electrochemiluminescence immunoassay in Alzheimer’s disease. Sci Rep. Jan 05 2024;14(1):629. doi:10.1038/s41598-024-51334-x
- VandeVrede L, La Joie R, Thijssen EH, et al. Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome. JAMA Neurol. May 01 2023;80(5):495-505. doi:10.1001/jamaneurol.2023.0488